People

Clinuvel’s Board of Directors

Mr Stanley McLiesh

Roles - Chairman, member of the Remuneration and Nomination Committee and the Audit and Risk Committee

Qualifications - BEd

Joined CUV Board - 2002

Biography

Dr Philippe Wolgen

Roles - Managing Director and Chief Executive Officer, Non-voting member of the Audit and Risk Committee and the Remuneration and Nomination Committee

Qualifications - MBA, MD

Joined CUV Board - 2005

Biography

Dr Helmer P K Agersborg

Roles - Executive Director, Deputy Chair and Chief Scientific Officer, member of the Remuneration and Nomination Committee

Qualifications - BSc, PhD

Joined CUV Board - 2001

Other affiliations - Director of Virxsys Corporation

Biography

Mr Jack Wood

Role - Non-Executive Director, Chair of the Remuneration and Nomination Committee

Qualifications - BComm

Joined CUV Board - 2008

Other affiliations - Chairman of EnGene Corporation; and Director of QLT

Biography

Mrs Brenda Shanahan

Roles - Non-Executive Director, Chair of the Audit and Risk Committee

Qualifications - BComm, FAICD, ASIA

Joined CUV Board - 2007

Other affiliations - Chair of St Vincent's Medical Research Institute in Melbourne; non-Executive Director of DMP Asset Management; non-Executive Director of Challenger Limited (ASX:CGF); and  Director of the Kimberley Foundation of Australia.

Biography

Mr Elie Ishag

Roles - Non-Executive Director

Joined CUV Board - 2011

Other affiliations - Chairman European Investments & Developments Ltd

Biography

Board Committee roles

 

 Remuneration and Nomination Committee

 Audit and Risk Committee

Mrs Brenda Shanahan

 

Chair

Dr Philippe Wolgen

Non-voting member

Non-voting member

Dr Helmer P K Agersborg

Member

 

Mr Stanley McLiesh

Member

Member

Mr Jack Wood

Chair

 

Mr Elie Ishag

 

 

Executive Management

Dr Dennis Wright

Role - Vice President, Scientific Affairs

Qualifications - BPharm, MSc, PhD

Biography

Mr Darren Keamy

Roles - Chief Financial Officer, Company Secretary

Qualifications - BComm, CPA

Biography

 

Note - Roles correct as at September 27, 2011.

Investors Related Blog Posts

Image

Online evolution...

Earlier this week we unveiled a major update to our online presence with the release of our new-look website... Read more...

Image

EPP results and clinical relevanc...

Over recent months I have written several times of the need for Clinuvel to prove clinical relevance in... Read more...

Image

The importance of clinical releva...

Development of novel drugs is truly like no other business: one attempts to address questions that may have... Read more...

Investors Related Videos

Part Four - The impact of Eryt...

Mikey's quality of life, like all patients with Erythropoietic Protoporphyria (EPP), is severely affected. Severe pain f... Watch now

Quick! I need Sunburn Relief! ...

There are many remedies available to help provide relief from the symptoms of sunburn. Treatment of sunburn can include:... Watch now

Understanding Vitiligo - Cause...

Vitiligo is a common pigmentary disorder in which the pigment producing cells of the skin (melanocytes) are absent or do... Watch now

JoomlaXTC K2 Content Wall - Copyright 2010 Monev Software LLC

Featured Content

Annual Report for the year ended 30 June 2011

Contents: INTRODUCTION | ERYTHROPOIETIC PROTOPORPHYRIA (EPP) | NONSEGMENTAL VITILIGO (NSV) | CLINUVEL BUSINESS MODEL | CORPORATE MILESTONES | CHAIR's LETTER | MANAGING DIRECTOR’S REPORT | FINANCIALS | ADDITIONAL INFORMATION REQUIRED BY THE ASX | MA... Read more

JoomlaXTC K2 Content Wall - Copyright 2010 Monev Software LLC